What is the test for?
Cquence NSCLC genotyping panel provides hopes for recovery and improves quality of life for non-small cell lung cancer (NSCLC) patients. About 80% of lung cancers are non-small cell lung cancers (NSCLC)1. There are over 4000 annual new cases of NSCLC in Hong Kong, killed about 3000, being the most prevalent and dangerous cancer type2.
How does this test help treat NSCLC?
This test enables doctors in determining the best medication for non-small cell lung cancer (NSCLC) patients. Cquence NSCLC genotyping panel is a precision medical test designed to determine and categorize (genotyping) EGFR and ALK along with 21 other genes related to NSCLC3,4. Finding out these cancer genes is important in making decisions and predicting responses for targeted-therapies and/or other treatments specific for the patient tested.
What are cancer genes and how are they related to NSCLC?
The major difference which separates a cancer cell from a normal cell is its uncontrolled cell growth with an exceptionally higher survival rate. These “enhanced” abilities are contributed by changes in the genetic information, or genes, of these cancer cells. Some renowned genes associated with NSCLC are EGFR and ALK. However, there are more than just EGFR and ALK that contribute to the activity of NSCLC.
Who should consider this test?
Patients who are suffering from NSCLC and/or patients who have received targeted therapy and failed to show signs of recovery are advised to perform this test.
How are samples obtained?
“Biopsy” is the surgical process which the doctor collects a section of suspected cancer tissue and sends it to the laboratory for analysis.
What should I do if my test results are positive?
Please consult your physicians for professional advices.